Plain-English translation of NCT02000687 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 1 Diabetes Mellitus research guide →This is a long-term follow-up study for people who have received an islet transplant (transplanted insulin-producing cells) that has stopped working. After your transplant fails, you'll stop taking your anti-rejection medications (sirolimus, tacrolimus, MMF, and Myfortic), and researchers will monitor your immune system for 10 years to see how your body responds to the failed transplant.
When an islet transplant fails, doctors need to understand what happens to the immune system after anti-rejection medications are stopped. This study fills an important gap by tracking whether patients develop increased immune sensitivity to the transplanted tissue over time, which could affect future transplant options.
You likely qualify if…
You likely don't qualify if…
After your islet transplant has failed, you will stop taking your anti-rejection medications under medical supervision. You will then come in for regular blood tests over 10 years to measure your immune markers and see how your body responds. The study focuses on blood work and monitoring rather than taking new medications or undergoing procedures.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Enrollment target
~60 participants
Started
December 2008
Primary completion
December 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in March 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.